Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Microwave Ablation + Lenvatinib for Recurrent HCC
NCT05444478Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jul 2022
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of lenvatinib in hepatocellular carcinoma (HCC) (2 arms), sponsored by Sun Yat-sen University. Primary endpoints: Tumor-free survival rate at 36 months and Overall survival (OS) rate at 36 months. Started Jul 2022; status: recruiting.
02
Drugs
lenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05444478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05444478.